Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17039011 | 0.92 | POLB (0.55) | POLBTP53HDAC6HDAC1HDAC8 | |
| SCHEMBL17039014 | 0.91 | POLB (0.52) | POLBHDAC6HDAC1HDAC8HDAC2 | |
| SCHEMBL17039026 | 0.90 | HDAC6 (0.55) | POLBTP53HDAC6HDAC1HDAC8 | |
| SCHEMBL17039018 | 0.90 | MAPT (0.48) | MEN1KMT2APOLBTP53HDAC6 | |
| SCHEMBL17038962 | 0.90 | POLB (0.48) | MEN1KMT2APOLBHDAC6HDAC1 | |
| SCHEMBL17195555 | 0.88 | HDAC6 (0.57) | MEN1KMT2APOLBTP53HDAC6 | |
| SCHEMBL17038968 | 0.87 | HTT (0.50) | MEN1KMT2APOLBTP53HDAC6 | |
| SCHEMBL17038748 | 0.86 | POLB (0.47) | MEN1KMT2APOLBHDAC6HDAC1 | |
| SCHEMBL17039009 | 0.86 | MAPT (0.55) | POLBHDAC6HDAC1HDAC8HDAC2 | |
| SCHEMBL17039007 | 0.85 | RXFP1 (0.49) | POLBHDAC6HDAC1HDAC8HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858929-B2 | Compounds and methods for inhibiting fascin | CORNELL UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | NOVITA PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-11701342-B2 | Co-therapies including a metastasis inhibitor | CORNELL UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210340138-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | NOVITA PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| EP-3107902-B1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIV CORNELL CENTER FOR TECHNOLOGY ENTERPRISE & COMMERCIALIZATION CCTEC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10941141-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200352911-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | CORNELL UNIVERSITY | 2020-11-12 | — | — | US | disclosed |
| US-20200039976-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2020-02-06 | — | — | US | disclosed |
| WO-2019104067-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | CORNELL UNIVERSITY (US) | 2019-05-31 | — | — | WO | disclosed |
| US-10227345-B2 | Compounds and methods for inhibiting fascin | CORNELL UNIVERSITY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180215757-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2018-08-02 | — | — | US | disclosed |
| US-9850243-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170158692-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2017-06-08 | — | — | US | disclosed |
| US-9573946-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150299191-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2015-10-22 | — | — | US | disclosed |
| WO-2015127125-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY (US) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299191-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | MEN1 3402/4885KMT2A 4757/4885POLB 1358/4885 |
| US-10227345-B2 | Compounds and methods for inhibiting fascin | FSCN1, MTPN, MYOF | MEN1 3402/4885KMT2A 4757/4885POLB 1358/4885 |
| US-20210340138-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | MEN1 3402/4885KMT2A 4757/4885POLB 1358/4885 |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | FSCN1, MTPN, MYOF | MEN1 3402/4885KMT2A 4757/4885POLB 1358/4885 |
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | MIF, CXCL10, CCL2 | MEN1 821/4885KMT2A 1480/4885POLB 1691/4885 |
| US-20180215757-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | MEN1 3402/4885KMT2A 4757/4885POLB 1358/4885 |
| US-20200352911-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | MIF, CXCL10, CCL2 | MEN1 821/4885KMT2A 1480/4885POLB 1691/4885 |
| US-20170158692-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | MEN1 3402/4885KMT2A 4757/4885POLB 1358/4885 |
| US-11701342-B2 | Co-therapies including a metastasis inhibitor | MIF, CXCL10, CCL2 | MEN1 821/4885KMT2A 1480/4885POLB 1691/4885 |
| US-10941141-B2 | Compounds and methods for inhibiting fascin | FSCN1, MTPN, MYOF | MEN1 3402/4885KMT2A 4757/4885POLB 1358/4885 |
| US-20200039976-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | MEN1 3402/4885KMT2A 4757/4885POLB 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.